Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01296191 · ClinicalTrials.gov registry record · Phase 4
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
A Phase 4 study of Cataracts, sponsored by Frank A. Bucci, Jr., M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT01296191 is a Phase 4 study of Cataracts that has completed, run by Frank A. Bucci, Jr., M.D.. The registered enrollment target is 120 participants, above the 83-participant average among 8 other Cataracts trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01296191, a Phase 4 study of Cataracts, has completed, sponsored by Frank A. Bucci, Jr., M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare drug concentrations in aqueous humor following ocular instillation of Besivance and VIGAMOX in subjects undergoing cataract surgery.
Conditions Studied
Interventions
- DRUG Moxifloxacin
- DRUG besifloxacin
Study Locations (1)
Pennsylvania
- Bucci Laser Vision Institute - Wilkes-Barre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01296191
The ClinicalTrials.gov registry entry for NCT01296191 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 8 other Cataracts trials with a reported enrollment target (45% higher). The listed sponsor is Frank A. Bucci, Jr., M.D., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataracts appearing as the primary indexed condition, and to 2 interventions - of which Moxifloxacin is the first listed.
NCT01296191 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01296191 about?
NCT01296191 is a clinical study titled "Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification". The purpose of this study is to compare drug concentrations in aqueous humor following ocular instillation of Besivance and VIGAMOX in subjects undergoing cataract surgery.
What is the current status of trial NCT01296191?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2011-05. Estimated completion is 2013-01.
What conditions does trial NCT01296191 study?
This clinical trial studies the following conditions: Cataracts.
What interventions are being tested in trial NCT01296191?
The interventions under investigation include: Moxifloxacin (DRUG), besifloxacin (DRUG).
Who is sponsoring clinical trial NCT01296191?
This trial is sponsored by Frank A. Bucci, Jr., M.D., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01296191 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataracts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
COMPLETED · Phase 4
-
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
COMPLETED · Phase 4
-
Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery
COMPLETED · Phase 4
-
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
COMPLETED · Phase 4
-
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.